Oppenheimer analyst Jay Olson raised the firm’s price target on Harmony Biosciences (HRMY) to $72 from $62 and keeps an Outperform rating on the shares. The firm attributes yesterday’s share rally to Harmony’s recent patent litigation defending Wakix, which it believes “helped dispel bears” that expected loss of exclusivity before 2030. Harmony has always appeared well positioned to defend the Wakix intellectual property, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony patent litigation update ‘major positive,’ says Mizuho
- Harmony jumps 14% to $33.58 after Mizuho uncovers new patent lawsuit
- Harmony extends rally, shares up 16% after Mizuho research note
- Harmony Biosciences Names New CFO to Drive Growth
- Harmony Biosciences appoints Reicin as Chief Financial Officer